The value of maintaining cognition in patients with mild cognitive impairment
| Autor: | Ron Handels, Sabine Grimm, Arjan Blokland, Nina Possemis, Inez Ramakers, Anke Sambeth, Frans Verhey, Stephanie Vos, Manuela Joore, Jos Prickaerts, Linus Jönsson |
|---|---|
| Přispěvatelé: | Psychology 2, RS: MHeNs - R1 - Cognitive Neuropsychiatry and Clinical Neuroscience, MUMC+: KIO Kemta (9), Section Psychopharmacology, RS: FPN NPPP II, Basic Neuroscience 2, RS: MHeNs - R3 - Neuroscience, Sect. Teaching & Innovation of Learning, RS: FPN STIL, Psychiatrie & Neuropsychologie, RS: CAPHRI - R2 - Creating Value-Based Health Care |
| Jazyk: | angličtina |
| Rok vydání: | 2023 |
| Předmět: | |
| Zdroj: | Alzheimer's & Dementia. Elsevier Science |
| ISSN: | 1552-5279 1552-5260 |
| DOI: | 10.1002/alz.13001 |
| Popis: | INTRODUCTION: Early health-technology assessment can support discussing scarce resource allocation among stakeholders. We explored the value of maintaining cognition in patients with mild cognitive impairment (MCI) by estimating: (1) the innovation headroom and (2) the potential cost effectiveness of roflumilast treatment in this population.METHODS: The innovation headroom was operationalized by a fictive 100% efficacious treatment effect, and the roflumilast effect on memory word learning test was assumed to be associated with 7% relative risk reduction of dementia onset. Both were compared to Dutch setting usual care using the adapted International Pharmaco-Economic Collaboration on Alzheimer's Disease (IPECAD) open-source model.RESULTS: The total innovation headroom expressed as net health benefit was 4.2 (95% bootstrap interval: 2.9-5.7) quality-adjusted life years (QALYs). The potential cost effectiveness of roflumilast was k€34 per QALY.DISCUSSION: The innovation headroom in MCI is substantial. Although the potential cost effectiveness of roflumilast treatment is uncertain, further research on its effect on dementia onset is likely valuable. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|